Armata Pharmaceuticals, Inc.
ARMP · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5,174 | $4,529 | $5,508 | $4,474 |
| % Growth | 14.2% | -17.8% | 23.1% | – |
| Cost of Goods Sold | $34,426 | $972 | $35,017 | $20,015 |
| Gross Profit | -$29,252 | $3,557 | -$29,509 | -$15,541 |
| % Margin | -565.4% | 78.5% | -535.7% | -347.4% |
| R&D Expenses | $34,426 | $33,770 | $35,017 | $20,015 |
| G&A Expenses | $13,184 | $0 | $7,437 | $8,281 |
| SG&A Expenses | $13,184 | $10,677 | $7,437 | $8,281 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$34,426 | $0 | -$35,017 | -$20,015 |
| Operating Expenses | $13,184 | $44,447 | $7,437 | $8,281 |
| Operating Income | -$42,436 | -$40,890 | -$36,946 | -$23,822 |
| % Margin | -820.2% | -902.8% | -670.8% | -532.5% |
| Other Income/Exp. Net | $23,520 | -$28,155 | $29 | $667 |
| Pre-Tax Income | -$18,916 | -$69,045 | -$36,917 | -$23,155 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18,916 | -$69,045 | -$36,917 | -$23,155 |
| % Margin | -365.6% | -1,524.5% | -670.2% | -517.5% |
| EPS | -0.523 | -1.91 | -1.08 | -0.96 |
| % Growth | 72.6% | -76.9% | -12.5% | – |
| EPS Diluted | -0.523 | -1.91 | -1.08 | -0.96 |
| Weighted Avg Shares Out | 36,161 | 36,076 | 34,294 | 24,104 |
| Weighted Avg Shares Out Dil | 36,161 | 36,076 | 34,294 | 24,104 |
| Supplemental Information | – | – | – | – |
| Interest Income | $697 | $179 | $29 | $5 |
| Interest Expense | $10,742 | $2,626 | $29 | $64 |
| Depreciation & Amortization | $1,325 | $972 | $892 | $1,169 |
| EBITDA | -$41,111 | -$65,447 | -$36,054 | -$21,922 |
| % Margin | -794.6% | -1,445.1% | -654.6% | -490% |